Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
第2相
完了
NCT02296684
| 対象疾患 | Cancer of Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck, Carcinoma, Squamous Cell of Head and Neck |
|---|
| 相 | 第2相 |
|---|
| スポンサー | Washington University School of Medicine |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 67 名 |
|---|
| 介入（薬剤） | MK-3475 (neoadjuvant), Surgery, Intensity modulated radiation therapy, Image-guided radiation therapy, Cisplatin |
|---|
| 開始日 | 2015年3月25日 |
|---|
| 完了日 | 2022年4月5日 |
|---|
| 結果公開日 | 2023年5月11日 |
|---|
概要
The goal of this trial is to test the ability of MK-3475 (pembrolizumab) to improve locoregional recurrence and distant metastatic rates in high-risk patients with locally advanced head and neck squamous cell carcinomas (HNSCCs) that are treated with current standard of care surgical approaches.
Locoregional Recurrence Rates in Cohorts 1 and 2
Within 1 year of surgery (surgery occurred within 13-22 days after neoadjuvant MK-3475 dose) · Participants
| Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475 | 2 Participants |
|---|
| Cohort 2: Neoadjuvant MK-3475 | 2 Participants |
|---|
Distant Failure Rate in Cohorts 1 and 2
Within 1 year of surgery (surgery occurred within 13-22 days after neoadjuvant MK-3475 dose) · Participants
| Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475 | 3 Participants |
|---|
| Cohort 2: Neoadjuvant MK-3475 | 1 Participants |
|---|
Rate of Major Pathologic Treatment Effect in Cohort 1
At the time of surgery (surgery occurred within 13-22 days after neoadjuvant MK-3475 dose) · Participants
| Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475 | 20 Participants |
|---|
| Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475 | 8 Participants |
|---|
| Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475 | 8 Participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。